EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Overview
NASDAQ:EPRX - CA29842P1053 - Common Stock
EPRX Key Statistics, Chart & Performance
The current stock price of EPRX is 5.22 USD. In the past month the price decreased by -3.85%. In the past year, price increased by 97.71%.
EPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.65 | 367.58B | ||
| AMGN | AMGEN INC | 13.22 | 155.27B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 141.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 100.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.62 | 61.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.50B | ||
| ARGX | ARGENX SE - ADR | 73.79 | 41.86B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.3 | 37.00B | ||
| INSM | INSMED INC | N/A | 27.58B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.66B | ||
| NTRA | NATERA INC | N/A | 22.34B | ||
| BIIB | BIOGEN INC | 8.56 | 20.09B |
Related stock screener links
About EPRX
Company Profile
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
Company Info
EUPRAXIA PHARMACEUTICALS INC
201-2067 Cadboro Bay Rd.
Victoria BRITISH COLUMBIA CA
Employees: 33
Phone: 12505903968
EUPRAXIA PHARMACEUTICALS INC / EPRX FAQ
What is the stock price of EUPRAXIA PHARMACEUTICALS INC today?
The current stock price of EPRX is 5.22 USD. The price decreased by -1.14% in the last trading session.
What is the ticker symbol for EUPRAXIA PHARMACEUTICALS INC stock?
The exchange symbol of EUPRAXIA PHARMACEUTICALS INC is EPRX and it is listed on the Nasdaq exchange.
On which exchange is EPRX stock listed?
EPRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EUPRAXIA PHARMACEUTICALS INC stock?
9 analysts have analysed EPRX and the average price target is 8.09 USD. This implies a price increase of 55.06% is expected in the next year compared to the current price of 5.22. Check the EUPRAXIA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EUPRAXIA PHARMACEUTICALS INC worth?
EUPRAXIA PHARMACEUTICALS INC (EPRX) has a market capitalization of 187.71M USD. This makes EPRX a Micro Cap stock.
How many employees does EUPRAXIA PHARMACEUTICALS INC have?
EUPRAXIA PHARMACEUTICALS INC (EPRX) currently has 33 employees.
What are the support and resistance levels for EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?
EUPRAXIA PHARMACEUTICALS INC (EPRX) has a support level at 5.26 and a resistance level at 5.32. Check the full technical report for a detailed analysis of EPRX support and resistance levels.
Should I buy EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EPRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EPRX, evaluating the profitability, health, valuation and growth aspects
- EUPRAXIA PHARMACEUTICALS INC (EPRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EUPRAXIA PHARMACEUTICALS INC (EPRX) Sales and EPS estimates to see what analysts future expectations are.
- EUPRAXIA PHARMACEUTICALS INC (EPRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EUPRAXIA PHARMACEUTICALS INC (EPRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Chart to make your own analysis
- EUPRAXIA PHARMACEUTICALS INC (EPRX) Latest news and press-releases to stay up to date.
Does EUPRAXIA PHARMACEUTICALS INC (EPRX) stock pay dividends?
EPRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of EUPRAXIA PHARMACEUTICALS INC (EPRX)?
EUPRAXIA PHARMACEUTICALS INC (EPRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.17).
What is the Short Interest ratio of EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?
The outstanding short interest for EUPRAXIA PHARMACEUTICALS INC (EPRX) is 0.6% of its float. Check the ownership tab for more information on the EPRX short interest.
EPRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EPRX. When comparing the yearly performance of all stocks, EPRX is one of the better performing stocks in the market, outperforming 94.65% of all stocks.
EPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPRX. EPRX has a great financial health rating, but its profitability evaluates not so good.
EPRX Financial Highlights
Over the last trailing twelve months EPRX reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS decreased by -2.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.7% | ||
| ROE | -91.67% | ||
| Debt/Equity | 0 |
EPRX Forecast & Estimates
9 analysts have analysed EPRX and the average price target is 8.09 USD. This implies a price increase of 55.06% is expected in the next year compared to the current price of 5.22.